Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: RETRACTED ARTICLE: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Fig. 5

Mitophagy is activated by sorafenib treatment and inhibited by LATS2 overexpression. a–d Proteins were isolated from HepG2 cells and then western blotting was used to observe the expression of mitophagy-related proteins. e, f Immunofluorescence assay for mitophagy. Green mitochondria and red lysosome were labeled and then the number of orange mitophagy was recorded in HepG2 cells. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. g, h Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us